When a company reports an 'efficacy estimate,' it often excludes patients who dropped out of a trial, inflating perceived success. Investors should demand the 'treatment regimen estimate,' which includes all participants and aligns with what the FDA actually considers for drug approval.

Despite sound science, many recent drug launches are failing. The root cause is not the data but an underinvestment in market conditioning. Cautious investors and tighter budgets mean companies are starting their educational and scientific storytelling efforts too late, failing to prepare the market adequately.

CEO Pravin Dugel anticipated the 27% stock drop following positive Phase 3 data, attributing it to the market's initial confusion over a new, complex study design. He believes that as investors digest the nuanced data showing superiority over a market leader, the valuation will correct, highlighting a common disconnect between biotech milestones and immediate market sentiment.

Investors often compare new drugs to the most effective treatments on efficacy alone. In practice, dermatologists will almost always choose a safer drug with lower efficacy first, creating a huge market for treatments that aren't "best-in-class" but have a superior safety profile.

The company reports 'overall MMR,' which includes patients maintaining a prior response—a less rigorous metric than 'MMR achievement' (new responses). The CEO notes that discerning investors are focused on the latter, more challenging endpoint, revealing a key area of due diligence for the company's impressive data.

The enzalutamide arms saw discontinuation rates of 20-25% due to adverse events. This high rate reflects a different risk calculation for patients who feel healthy and are asymptomatic. Unlike in advanced disease where patients tolerate more toxicity, this population has a very low threshold for side effects, making early intervention a significant trade-off.

Contrary to market convention, a trial delay can be a bullish signal. When an independent data monitoring committee (IDMC) recommends adding more patients, as with Bristol's ADEPT-2 study, it implies they've seen a therapeutic signal worth salvaging, potentially increasing the trial's ultimate chance of success.

When questioned about discrepancies where a 24-week dose underperformed on the primary endpoint but was strong on secondary ones, the CEO avoided direct comparisons. Instead, he framed the results as a 'totality of evidence' supporting the drug's profile, a key communication tactic for presenting complex or imperfect data positively to investors and regulators.

Experts believe the stark difference in complete response rates (5% vs 30%) between two major ADC trials is likely due to "noise"—variations in patient populations (e.g., more upper tract disease) and stricter central review criteria, rather than a fundamental difference in the therapies' effectiveness.